Immutep Competitors

Immunome (NASDAQ:IMNM) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Immunome and Immutep's gross revenue, earnings per share (EPS) and valuation.

Immutep has higher revenue and earnings than Immunome.

Analyst Ratings

This is a summary of recent ratings for Immunome and Immutep, as provided by MarketBeat.com.

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 54.52%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's higher possible upside, analysts clearly believe Immutep is more favorable than Immunome.

Insider & Institutional Ownership

0.2% of Immutep shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunome and Immutep's net margins, return on equity and return on assets.

Summary

Immutep beats Immunome on 4 of the 4 factors compared between the two stocks.

Kala Pharmaceuticals (NASDAQ:KALA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Kala Pharmaceuticals and Immutep's net margins, return on equity and return on assets.

Insider & Institutional Ownership

67.6% of Kala Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 34.2% of Kala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Kala Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Earnings and Valuation

This table compares Kala Pharmaceuticals and Immutep's gross revenue, earnings per share (EPS) and valuation.

Immutep has lower revenue, but higher earnings than Kala Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings for Kala Pharmaceuticals and Immutep, as provided by MarketBeat.com.

Kala Pharmaceuticals presently has a consensus price target of $20.8571, indicating a potential upside of 181.47%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Kala Pharmaceuticals' higher possible upside, analysts clearly believe Kala Pharmaceuticals is more favorable than Immutep.

Cue Biopharma (NASDAQ:CUE) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Cue Biopharma and Immutep's net margins, return on equity and return on assets.

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Cue Biopharma has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cue Biopharma and Immutep's gross revenue, earnings per share and valuation.

Immutep has higher revenue and earnings than Cue Biopharma.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cue Biopharma and Immutep, as provided by MarketBeat.

Cue Biopharma presently has a consensus price target of $31.00, indicating a potential upside of 127.77%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's higher possible upside, analysts plainly believe Immutep is more favorable than Cue Biopharma.

Summary

Immutep beats Cue Biopharma on 7 of the 11 factors compared between the two stocks.

Fulcrum Therapeutics (NASDAQ:FULC) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Fulcrum Therapeutics and Immutep's net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.5% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 30.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Fulcrum Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Fulcrum Therapeutics and Immutep's gross revenue, earnings per share and valuation.

Immutep has higher revenue and earnings than Fulcrum Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fulcrum Therapeutics and Immutep, as provided by MarketBeat.

Fulcrum Therapeutics presently has a consensus price target of $18.1667, indicating a potential upside of 44.07%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's stronger consensus rating and higher possible upside, analysts plainly believe Immutep is more favorable than Fulcrum Therapeutics.

Summary

Immutep beats Fulcrum Therapeutics on 7 of the 10 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Evolus and Immutep's net margins, return on equity and return on assets.

Insider and Institutional Ownership

21.7% of Evolus shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 10.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Valuation and Earnings

This table compares Evolus and Immutep's gross revenue, earnings per share and valuation.

Immutep has lower revenue, but higher earnings than Evolus.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Evolus and Immutep, as provided by MarketBeat.

Evolus presently has a consensus price target of $13.00, indicating a potential upside of 7.35%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Immutep's stronger consensus rating and higher possible upside, analysts plainly believe Immutep is more favorable than Evolus.

Summary

Immutep beats Evolus on 7 of the 12 factors compared between the two stocks.

Athersys (NASDAQ:ATHX) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Athersys and Immutep, as provided by MarketBeat.

Athersys presently has a consensus price target of $9.00, indicating a potential upside of 341.18%. Immutep has a consensus price target of $7.00, indicating a potential upside of 161.19%. Given Athersys' higher possible upside, equities analysts plainly believe Athersys is more favorable than Immutep.

Profitability

This table compares Athersys and Immutep's net margins, return on equity and return on assets.

Volatility & Risk

Athersys has a beta of -1.54, indicating that its stock price is 254% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Insider and Institutional Ownership

27.9% of Athersys shares are owned by institutional investors. Comparatively, 0.2% of Immutep shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Athersys and Immutep's gross revenue, earnings per share and valuation.

Immutep has lower revenue, but higher earnings than Athersys.

Summary

Athersys beats Immutep on 6 of the 10 factors compared between the two stocks.